A randomized controlled trial on the hemostasis of femoral artery using topical hemostatic agent

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 5, 2012, Pages 501-505

  Kordestani, Soheila S ^a   Noohi, Fereidoon ^b   Azarnik, Hossein ^b   Basiri, Hossein ^b   Hashemi, M J ^b   Abdi, S ^b   Mohebi, A ^b   Madani, M ^b   Nayebhabib, Farzaneh ^a  

^a AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cellulose; coronary angiography; femoral artery; hemostasis; hemostatics

Indexed keywords

CHITOHEM; HEMOSTATIC AGENT; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; COMPRESSION THERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMORAL ARTERY; HEMATOMA; HEMOSTASIS; HUMAN; MOBILIZATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT;

ADMINISTRATION, TOPICAL; AGED; CORONARY ANGIOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; HEMATOMA; HEMOSTATIC TECHNIQUES; HEMOSTATICS; HUMANS; MIDDLE AGED;

EID: 84865516758     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611432745     Document Type: Article

References (31)

1. Schickel S, Cronin SN, Mize A, Voelker C. Removal of femoral sheaths by registered nurses: issues and outcomes. Crit Care Nurse. 1996 ; 16 (2). 32-36
2. Lehmann KG, Ferris ST, Heath-Lange SJ. Maintenance of hemostasis after invasive cardiac procedures: implications for outpatient catheterization. J Am Coll Cardiol. 1997 ; 30 (2). 444-451
3. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization. JAMA. 2004 ; 291 (3). 350-357
4. Roebuck A, Jessop R, Turner R, Caplin JL. The safety of two-hour versus four-hour bed rest after elective 6-french femoral cardiac catheterization. Coronary Health Care. 2000 ; 4 (4). 169-173
5. Beattie S. Cut the risks for cardiac cath patients. RN. 1999 ; 62 (1). 50-54
6. Björses K, Holst J. Various local hemostatic agents with different modes of action; an in vivo comparative randomized vascular surgical experimental study. Eur J Vasc Endovasc Surg. 2007 ; 33 (3). 363-370
7. Cassara K, Bachoob P, Fordc I, Greavesc M, Brittendena J. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2005 ; 29 (2). 171-176
8. Nasser TK, Mohler ER 3rd, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol. 1995 ; 18 (11). 609-614
9. Applegate RJ, Grabarczyk MA, Little WC, et al. Vascular closure devices in patients treated with anticoagulation andIIb/IIIa receptor inhibitors during percutaneous evascularization. J Am Coll Cardiol. 2002 ; 40 (1). 78-83
10. Waksman R, King SB 3rd, Douglas JS, et al. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol. 1995 ; 75 (14). 886-889
11. Omoigui NA, Califf RM, Pieper K, et al. Peripheral vascular complications in the coronary angioplasty versus excisional artherectomy trial (CAVEAT-I). J Am Coll Cardiol. 1995 ; 26 (4). 922-930
12. Kussmaul WG 3rd, Buchbinder M, Whitlow PL, et al. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 ; 25 (7). 1685-1692
13. Trisnohadi HB. Rapid hemostasis of arterial puncture sites with angio-seal in patients undergoing percutaneous coronary intervention. Acta Med Indones. 2005 ; 37 (2). 87-90
14. Martin JL, Pratsos A, Magargee E, et al. A randomized trial comparing compression, perclose proglide and angio-seal VIP for arterial closure following percutaneous coronary intervention: the CAP trial. Catheter Cardiovasc Interv. 2008 ; 71 (1). 1-5
15. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol. 2004 ; 44 (6). 1200-1209
16. Mego D, Thomas M, Stewart J, et al. A Poly-N-acetyl glucosamine hemostatic dressing for femoral artery access site hemostasis after percutaneous coronary intervention: a pilot study. J Invasive Cardiol. 2010 ; 22 (1). 35-39
17. Wahlgren C, Swedenborg J. The use of recombinant activated factor VII to control bleeding during repair of a suprarenal abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2003 ; 26 (2). 221-222
18. Carey D, Martin JR, Moore CA, et al. Complications of femoral artery closure devices. Catheter Cardiovasc Interv. 2001 ; 52 (1). 3-7
19. Dangas G, Mehran R, Kokolis S, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol. 2001 ; 38 (3). 638-641
20. Unlü Y, Vural U, Koçak H, Ceviz M, Becit N, Akbulut O. Comparison of the topical haemostatic agents for the prevention of suture hole bleeding. An experimental study. Eur J Vasc Endovasc Surg. 2002 ; 23 (5). 441-444
21. ChitoTech Inc. www.chitotech.com
22. Jones T, McCutcheon H. Effectiveness of mechanical compression devices in attaining hemostasis after femoral sheath removal. Am J Crit Care. 2002 ; 11 (2). 155-162
23. Pracyk JB, Wall TC, Longabaugh JP, et al. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. Am J Cardiol. 1998 ; 81 (8). 970-976
24. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, et al. Ultrastructural and morphological analyses of the In Vitro and In Vivo hemostatic effects of ankaferd blood stopper. Clin Appl Thromb Hemost. 2010 ; 16 (4). 446-453
25. Cipil HS, Kosar A, Kaya A, et al. In Vivo hemostatic effect of the medicinal plant extract ankaferd blood stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost. 2009 ; 15 (3). 270-276
26. Hanks JB, Kjaergard HK, Hollingsbee DA. A Comparison of the Haemostatic Effect of Vivostat® Patient-Derived Fibrin Sealant with Oxidised Cellulose (Surgicel®) in Multiple Surgical Procedures. Eur Surg Res. 2003 ; 35 (5). 439-444
27. Nur I, Lyahovetsky Y, Bar L, Schon M. Commercial fibrin sealants are not equivalent in a rabbit liver-resection model which quantitatively evaluates hemostasis and formation of adhesions. Eur Surg Res. 2005 ; 37 (3). 159-165
28. Mlekusch W, Dick P, Haumer M, Sabeti S, Minar E, Schillinger M. Arterial puncture site management after percutaneous transluminal procedures using a hemostatic wound dressing (Clo-Sur P.A.D.) versus conventional manual compression: a randomized controlled trial. J Endovasc Ther. 2006 ; 13 (1). 23-31
29. Christensen BV, Manion RV, Iacarella CL, et al. Vascular complications after angiography with and without the use of sandbags. Nurs Res. 1998 ; 47 (1). 51-53
30. Juran NB, Rouse CL, Smith DD, O'Brien MA, DeLuca SA, Sigmon K. Nursing interventions to decrease bleeding at the femoral access site after percutaneous coronary intervention. Am J Crit Care. 1999 ; 8 (5). 303-313
31. Yilmaz E, Gürgün C, Dramali A. Minimizing short-term complications in patients who have undergone cardiac invasive procedure: a randomized controlled trial involving position change and sandbag. Anadolu Kardiyol Derg. 2007 ; 7 (4). 390-396